CAMBRIDGE, Mass. (AP) _ Epizyme Inc. (EPZM) on Tuesday reported a loss of $55.5 million in its first quarter.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 38 cents. Losses, adjusted for non-recurring gains, were 39 cents per share.
The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 35 cents per share.
The biopharmaceutical company posted revenue of $8.7 million in the period, also falling short of Street forecasts. Three analysts surveyed by Zacks expected $10.9 million.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on EPZM at https://www.zacks.com/ap/EPZM
Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News